Comparative study of the effect of neuromuscular electrical stimulation and oral administration of branched-chain amino acid on preventing sarcopenia in patients after living-donor liver transplantation: study protocol for an open-label randomized controlled trial by Haraguchi Masafumi et al.
STUDY PROTOCOL Open Access
Comparative study of the effect of
neuromuscular electrical stimulation and
oral administration of branched-chain
amino acid on preventing sarcopenia in
patients after living-donor liver
transplantation: study protocol for an open-
label randomized controlled trial
Masafumi Haraguchi1†, Kunihiro Ichinose2†, Hisamitsu Miyaaki1* , Masatoshi Hanada3, Masanori Fukushima1,
Ryu Sasaki1, Satoshi Miuma1, Takanobu Hara4, Tota Kugiyama4, Akihiko Soyama4, Masaaki Hidaka4, Ayumi Tsuji5,
Rintaro Yano6, Motohiro Sekino6, Hideaki Takahata3, Susumu Eguchi4 and Kazuhiko Nakao1
Abstract
Background: Liver cirrhosis is the irreversible fibrosis of the liver and causes refractory ascites and hepatic encephalopathy,
which might not respond to treatment. Living donor liver transplantation (LDLT) is an effective treatment for patients with
cirrhosis. However, post-LDLT patients are prone to muscle atrophy and sarcopenia. Therefore, physiotherapy of post-LDLT
patients is essential for preventing the progression of sarcopenia. Recently, rehabilitation using neuromuscular electrical
stimulation (NMES) has been reported to be useful for preventing the progression of sarcopenia. Similarly, nutrition therapy is
essential for post-LDLT patients because these patients frequently experience malnutrition. However, the effects of combined
NMES and nutrition therapy on post-LDLT patients remain unknown.
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Methods/design: This open-label, randomized, parallel-group study will compare the effects of combined therapy with
NMES and branched-chain amino acids (BCAA) with those of NMES alone in patients with decompensated cirrhosis after
LDLT. After LDLT, 50 patients with decompensated cirrhosis will be randomly assigned to receive NMES with BCAA or NMES
without BCAA. The duration of the intervention will be 3months. To analyze the change in skeletal muscle mass, InBody 770
body composition and body water analysis and ultrasonography will be performed before LDLT and 4 weeks and 12 weeks
post-LDLT. The primary endpoint is changes in the skeletal muscle mass from baseline to 3months. Important secondary
endpoints are the changes in the skeletal muscle mass from baseline to 1month and changes in the quadriceps strength
from baseline to 1month.
Discussion: The results of this study are expected to provide evidence regarding the effect of NMES combined with BCAA
therapy on the skeletal muscle of post-LDLT patients.
Trial registration: Japan Registry of Clinical Research jRCTs071190051. Registered on February 26, 2020.
Keywords: Branched-chain amino acids, Decompensated cirrhosis, Living donor liver transplantation, Neuromuscular
electrical stimulation, Sarcopenia
Background
Liver cirrhosis is the irreversible fibrosis of the liver; it
has various causes and is classified into compensated cir-
rhosis and decompensated cirrhosis [1]. Patients with
decompensated cirrhosis often experience complicating
refractory ascites and hepatic encephalopathy, which
might not respond to systemic treatment [2, 3]. Living
donor liver transplantation (LDLT) is an effective treat-
ment for patients with decompensated cirrhosis. How-
ever, such patients often develop muscle atrophy and
sarcopenia, leading to decreased quality of life [4–6]. Ex-
acerbation of sarcopenia affects the prognosis of patients
with cirrhosis [7]. Moreover, after LDLT, there are many
factors that limit post-operative weaning, such as an un-
stable fluid balance due to decreased hepatic metabolism
and associated retention of pleural effusion and ascites
[8], which lead to muscle atrophy and sarcopenia.
Physical therapy is considered essential post-LDLT to
facilitate motor function recovery [9–11]. Additionally,
physical performance potentially increases with the re-
covery of liver function [12]. Since recovery after trans-
plantation differs markedly across patients, no specific
protocols have been established for postoperative phys-
ical therapy.
Recently, rehabilitation using neuromuscular electrical
stimulation (NMES) has been reported to be useful for
preventing the decline in the activities of daily living
(ADLs) [13]. NMES is a practical, passive therapy that can
be safely applied to maintain quadriceps muscle mass in
seriously ill patients [14]. We have previously reported
that NMES, combined with conventional physical therapy,
significantly improved muscle mass in post-LDLT pa-
tients, compared with physical therapy alone [15].
Furthermore, after LDLT, patients are frequently mal-
nourished. Hence, nutrition therapy, as well as rehabilita-
tion, is essential after LDLT. A previous report indicated
that nutritional status and metabolism were improved by
adding branched-chain amino acids (BCAA) for 4 weeks
after LDLT [16]. However, the effects of a combination of
BCAA and NMES on patients after LDLT remain un-
known. Therefore, there is a need to evaluate the effects of
postoperative adjuvant therapies, such as physical therapy
and nutritional therapy, on preventing the decline in
ADLs due to muscle atrophy or exacerbation of sarcope-
nia after LDLT in patients with decompensated cirrhosis.
This study will aim to determine whether NMES and
BCAA combination therapy can contribute to the recov-
ery of skeletal muscle mass in patients with decompen-
sated cirrhosis after LDLT.
Methods/design
Study design
This is a pilot trial to assess the effect of NMES and
BCAA combination therapy on skeletal muscle mass.
We have designed a single-center, randomized, open-
label, parallel-group, active-controlled trial for patients
with decompensated cirrhosis scheduled to undergo
LDLT. We will randomly assign 50 patients, in a 1:1 ra-
tio, to the NMES and BCAA group or the control group
(receiving treatment with NMES only). The overall ob-
jective is to test for the superiority of the NMES and
BCAA group compared with the control group. The
study follow-up duration will be 3months. The study
will be conducted at Nagasaki University Hospital, Japan,
and the study design is summarized in Fig. 1.
Outcomes
The primary outcome measures are changes in the skel-
etal muscle mass, as determined using the InBody 770
(InBody, Tokyo, Japan). For this parameter, any change
will be determined based on the difference between the
measurement results at baseline (day 0) and 3months
post-LDLT.
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The study’s secondary outcome measures are as fol-
lows: changes in the skeletal muscle mass from baseline
to 1month post-LDLT; changes in the Skeletal Muscle
Index (SMI), as determined by the InBody 770; changes
in quadriceps muscle thickness, as determined by real-
time B-mode ultrasonography (ProSound 2; Hitachi-
Aloka Medical Co., Tokyo, Japan); quadriceps strength,
as determined by a handheld dynamometer fixed with a
belt (μ-Tas F−1; Anima Corporation, Tokyo, Japan); and
handgrip strength from baseline (day 0) to 1 month and
3months post-LDLT.
Sample size estimation
This is a trial to assess the changes in skeletal muscle
mass by NMES and BCAA combination therapy as com-
pared with NMES only. There is no prior similar study
that can be used to estimate the precise optimal sample
size. We estimated sample size with reference to a study
published by Koya et al. in 2017 [17]. This was a retro-
spective study comparing the skeletal muscle mass be-
fore and after transarterial chemoembolization (TACE)
in 54 hepatocellular carcinoma patients who were reha-
bilitated for 1 week after TACE; the study reported that
the presence or absence of BCAA affected changes in
muscle mass. We set the number of cases based on the
average and the variance-covariance matrix of the SMM
value, before and after treatment in the BCAA group
and the non-BCAA group, obtained from this study.
The justification for this sample size is based on the ra-
tionale concerning feasibility and precision regarding the
mean and variance of the primary outcome measures.
Patients and public involvement statement
There is no patient or public involvement in this trial.
Participants and recruitment
Fifty participants aged ≥ 20 years will be recruited into
the study. The enrollment started in February 2020. All
participants have been diagnosed with decompensated
liver cirrhosis and will undergo LDLT. Patients who ful-
fill the inclusion criteria described below will be invited
for eligibility screening. The transplant coordinator in-
forms investigators of the patients scheduled for LDLT.
The principal investigator and co-investigators recruit
the participants among these patients and obtain written
informed consent from the participants. The principal
investigator is responsible for obtaining informed con-
sent, and there are no additional consent provisions for
the collection and use of participant data and biological
specimens in ancillary studies. The recruitment rate and
the consent rate will be evaluated at the end of the
study.
Inclusion criteria
As shown in Fig. 1, participants must fulfill the following
criteria to be eligible for inclusion at their first visit to
Fig. 1 Study design. An eligibility check is conducted, and the patient’s informed consent is obtained at visit 1. The patients who satisfy the inclusion
criteria are enrolled in the study at visit 2; they are randomized in a 1:1 ratio to the NMES and BCAA group (administered Aminoleban EN 100mg) and
the control group. BCAA, branched-chain amino acids; LDLT, living donor liver transplantation; NMES, .neuromuscular electrical stimulation
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Nagasaki University Hospital (visit 1): (1) aged ≥ 20
years, (2) either sex, (3) diagnosis of decompensated liver
cirrhosis, (4) Performance Status (ECOG PS) of 0–2, and
(5) written informed consent provided.
Exclusion criteria
Eligible participants will be excluded if they meet any of
the following criteria: patients with decompensated liver
cirrhosis (1) complicated by a bone or a joint disorder that
might affect the effectiveness of NMES; (2) complicated
by a fragile skin disease, which might suffer damage due
to NMES; (3) complicated with a cerebrovascular disorder;
(4) undergoing hemodialysis; (5) complicated by amino
acid metabolism abnormalities; (6) who are pregnant or
lactating; (7) participating in other clinical research within
4months before enrollment; (8) complicated by chronic
heart disease or using a pacemaker; (9) complicated by
malignancy other than hepatocellular carcinoma; (10)
complicated by active infections or tuberculosis; (11) com-
plicated by severe hypertension; (12) complicated by ex-
treme weakness; (13) who will undergo Deceased Donor
Living Transplantation; (14) who are being included in
other trials (all drugs and interventions are permitted dur-
ing this trial); and (15) otherwise deemed inappropriate by
the study’s principal investigator.
Withdrawal criteria
Participants will be withdrawn from this trial after
randomization if they meet any of the following criteria:
(1) if they have requested a withdrawal from the study;
(2) if it is determined by the investigators that it is in-
appropriate for the patient to continue participating in
the study because of the progression of an underlying
disease or a complication or the occurrence of an un-
known disease; (3) if any adverse event that is ≥ grade 3
of the Common Terminology Criteria for Adverse
Events (CTCAE) ver. 4.0 occurs; (4) if the patient has
been in the intensive care unit for more than 1month;
and (5) if the investigators judge that it is inappropriate
for the patient to continue participating in the study for
any other reason.
Ethical considerations
This protocol was approved by the Clinical Research Re-
view Board of Nagasaki University (CRB7180001), which
is certified by Japan’s Ministry of Health, Labor, and
Welfare (approval no. CRB19-0015). The study is regis-
tered in the Japan Registry of Clinical Trials as
jRCTs071190051. The study will be conducted in ac-
cordance with the 7th revision of the Declaration of
Helsinki 2013 and the Clinical Trials Act enforced in
April 2020 in Japan. Any protocol modifications will be
communicated to the Clinical Research Review Board at
Nagasaki University and registered on the jRCT.
Setting and study timeline
All participants will be recruited at Nagasaki University
Hospital. Each participant’s information, as listed below,
is collected at the prescreening for enrollment (visit 1):
age, sex, height, body weight, history, comorbid compli-
cations, duration of cirrhosis, and history of cirrhosis
treatment. Blood pressure and pulse rate will be mea-
sured in a sedentary position at every visit (visits 1–5,
and, if withdrawing from the study, at withdrawal). As
shown in Table 1, the participants will undergo exami-
nations by blood tests, InBody 770 body composition
analysis, and handgrip and quadriceps strength evalua-
tions at enrollment (visit 1) and 1month (visit 4) and 3
months (visit 5) thereafter. Similarly, they will undergo
an examination of quadriceps strength at every visit, ex-
cept at the start of BCAA (visit 2). When participants
need to be withdrawn from the study for any reason,
their vital signs will be checked, and they will undergo
blood tests within 4 weeks after discontinuing the inves-
tigation. Blood specimens are to be obtained at visits 1,
4, and 5.
Laboratory measurements
At visits 1, 4, and 5, we will measure the patients’
complete blood count, prothrombin time-international
normalized ratio, and plasma levels of aspartate amino-
transferase, alanine aminotransferase, total bilirubin, albu-
min, C-reactive protein, hyaluronic acid, type IV collagen,
Wisteria floribunda agglutinin-positive Mac-2-binding
protein (WFA+-M2BP), ammonia, and cystatin C.
Randomization and allocation concealment
A randomized, open-label, parallel pilot trial design has
been set up. On the day on which the study drug is to
be firstly administered (visit 2), i.e., after the eligibility
assessment, each participant will be sequentially allo-
cated to either the NMES and BCAA group or the con-
trol group (NMES only), in a 1:1 ratio, using blocked
randomization stratified by age, sex, albumin level, and
Child-Pugh score. The allocation will be conducted by
the principal investigator using the Internet Data and In-
formation Center for Medical Research (INDICE) system
of UMIN.
Interventions
NMES and BCAA group
Participants allocated to the NMES and BCAA group
will undergo NMES within 7 days after LDLT and will
be given a BCAA-enriched snack (Aminoleban EN,
Otsuka Pharmaceutical Co., Tokyo, Japan; 100 mg/day)
after leaving the intensive care unit (ICU) daily for 1
month.
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Control group
Participants allocated to the control group will undergo
only NMES within 7 days after LDLT for 1 month in
addition to their previous treatment.
Both groups will receive muscle stimulation via
placement of rectangular electrodes (90 × 50 mm) over
the motor points of the quadriceps muscles (~ 5 cm
distal to the inguinal fold and 15 cm proximal to the
upper border of the patella) bilaterally. The stimulator
(Pulsecure-Pro KR-7; OG Giken Co., Tokyo, Japan)
delivers biphasic, symmetrical impulses (45 Hz; 400-μs
pulse duration; 12 s on and 6 s off; intensity, 40–80
mA). The amplitude is increased to elicit visible
muscle contractions and to the maximum level toler-
ated by the patients. Neuromuscular electrical stimu-
lation sessions in both groups are conducted for 30
min per session, once per day, every weekday over a
4-week period, by a physical therapist, beginning on
postoperative day 1 and continuing through postoper-
ative day 30.
During this study, all intervention procedures will be
checked by the attending physicians and a transplant co-
ordinator in the Nagasaki University Hospital to improve
adherence to intervention protocols.
Adverse events
All adverse events (AEs) that occur during the trial will
be recorded on a case report form and will be reviewed
as part of central data monitoring. Investigators will ex-
plain AEs to the participants and offer appropriate care.
All treatments will be performed within the Health and
Medical Services during this study. If serious AEs, such
as death, a life-threatening condition, hospitalization, se-
quelae, disability, and congenital illness, occur during
the trial, the principal investigator will report the AE to
the Minister of Health, Labor, and Welfare of Japan and
the certified review board within 15 days.
Data collection, data management, and monitoring
All data will be recorded in a case report form (CRF) by
either the investigator or the clinical research coordin-
ator. Only the patient identification number will be re-
corded in the CRF to ensure anonymization is
maintained. The list associating the case number to per-
sonal information, to enable records to be identified, will
be maintained in a secure fashion by the principal inves-
tigator. During the study, authorized investigators will
make regular site visits to review protocol compliance,
conduct source data verification, assess laboratory
Table 1 The schedule of pre-screening, interventions, and assessments
○ Will be done. A range of ±3 days is allowed for each visit dayThe examination at withdrawal is to be performed within 4 weeks from the date of withdrawal
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procedures, and ensure that the investigation is being
conducted according to protocol requirements. Once
the data are checked, they will be fixed by the trial steer-
ing committee (TSC). The TSC provides overall supervi-
sion for the trial to ensure that it is conducted in
accordance with the rigorous standards established in
the guidelines of the Clinical Trials Act. TSC comprises
three researchers (MH, MF, and RS), who will meet and
analyze the ongoing results of the research. No public
organizations are involved in the study development.
Statistical analyses
As stated in the Objectives section, the primary outcome
of this study is the extent of the effects of BCAA on
skeletal muscle mass after LDLT. Hence, the principal
data analysis will be conducted using the set of partici-
pants with sufficient exposure to the allocated drugs.
Therefore, we will use a per-protocol set (PPS). The
same analysis will be conducted on the full analysis set
(FAS). The respective analysis sets are defined as follows:
the intention-to-treat (ITT) population is defined as all
participants registered for this trial; the safety analysis
set (SAS) population is defined as the participants in the
ITT population that are administered NMES and
BCAA-enriched snack at least once. The full analysis set
(FAS) population is defined as the participants in the
SAS for whom data about the predicted bone strength
after the administration of NMES and BCAA-enriched
snacks at one or more scheduled visits are available. PPS
is a subset of FAS that excludes patients with major
protocol violations and, thus, represents greater compli-
ance with the protocol. Other criteria for the PPS will be
determined before the database lock of this study. As a
safety analysis, tabular summaries of AE incidence will
be created. All hypothesis testing will be conducted at a
significance level of 0.05 (two-sided). The data collected
will be summarized using the arithmetic mean, the
standard deviation, and the quantiles, and all statistical
analyses are to be performed using JMP 14.0 software
(SAS Institute Japan, Tokyo, Japan).
Plans for communication of trial results and data access
Plans for communication of trial results include presen-
tation at one or more national or international scientific
meetings and publication in a peer-reviewed journal.
The investigators plan to eventually make the final trial
data set publicly available.
Discussion
The primary purpose of this study is to determine
whether NMES and BCAA combination therapy contrib-
ute to the recovery of skeletal muscle mass in patients
with decompensated cirrhosis after LDLT.
Sarcopenia is one of the most common complications
of several chronic diseases, including chronic liver dis-
ease. The recent definition of sarcopenia includes the
presence of both low skeletal muscle mass and poor
skeletal muscle function [18]. Sarcopenia has been asso-
ciated with mortality in patients who have undergone
LDLT; perioperative nutrition therapy has been shown
to improve overall survival in patients with sarcopenia
significantly [19]. In other words, increasing skeletal
muscle mass and enhancing its function are essential
points for promoting postoperative weaning after LDLT
and improving overall survival.
BCAA are the essential amino acids valine, leucine, and
isoleucine, which form the substrates for protein synthesis
and energy generation in skeletal muscle [20, 21]. Several
reports have shown that BCAA supplementation helps pa-
tients with liver cirrhosis recover from protein-energy
malnutrition, raise serum albumin levels and subsequently
improve the quality of life and survival [22, 23]. Previous
reports have shown recovery of muscle mass after LDLT
with the administration of BCAA [16]. One possible rea-
son for the effect of BCAAs on sarcopenia is that leucine,
one of the BCAAs, activates the rapamycin signaling path-
way, which is involved in protein synthesis in muscle, and
further stimulates pancreatic beta cells to release anabolic
insulin in skeletal muscle [24].
Early administration of nutrition after transplant has
been associated with a worse prognosis among seriously
ill patients, suggesting that protein loading during the
hypercatabolic state may negatively influence prognosis
[25]. However, a previous study reported that the nutri-
tional state and metabolism were improved by BCAA
supplementation that was initiated on post-LDLT day 3
for a duration of 4 weeks [16]. BCAA supplementation
did not improve the length of stay in the ICU or the
total days of hospitalization. Based on this evidence, we
will initiate BCAA supplementation after discharge from
the ICU and not earlier in the course of post-LDLT
recovery.
In recent years, NMES has been used to improve
muscle strength and hypertrophy by contracting muscles
with percutaneous low-frequency electrical stimulation.
It has been reported that NMES improved muscle
strength of the lower limb muscle group in seriously ill
patients [26]. We have previously reported that NMES,
combined with conventional physical therapy, signifi-
cantly improved muscle mass in post-LDLT patients, as
compared with physical therapy alone [15]. However,
quadriceps muscle strength after LDLT was not suffi-
ciently recovered, and ADL was not improved by this
method. Therefore, we will investigate whether the
addition of BCAA to NMES can improve quadriceps
muscle strength and ADL post-LDLT.
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There are some limitations to the trial. First, the sam-
ple size is small (n = 50). Second, the follow-up period of
the examination may be insufficient to derive a definitive
conclusion regarding the effect of NMES and BCAA
therapy on sarcopenia after LDLT. Third, we cannot
deny that other factors, such as postoperative complica-
tions, will influence the participants’ muscle atrophy.
Despite these limitations, our planned research also
has some strengths. There has been no study assessing
the effect of NMES and BCAA therapy on patients with
decompensated cirrhosis. We will be able to elucidate
the effect of NMES and BCAA treatment on sarcopenia
using the InBody 770, which provides precise informa-
tion on body composition. Additionally, ultrasonography
and quadriceps dynamometer measurements will be use-
ful for the evaluation of muscle atrophy.
In conclusion, LDLT is an effective treatment for de-
compensated liver cirrhosis patients showing poor im-
provement in response to medical treatment. However,
this treatment is often accompanied by advanced inva-
sion, which often results in a decline of ADL, such as a
disuse syndrome, requiring long-term hospitalization. If
the combination of NMES and BCAA is shown to be
more effective than conventional treatment, it is ex-
pected to lead to better ADL and earlier discharge of pa-
tients after LDLT.
Trial status
The recruitment is to be conducted from March 2020 to
December 2023. The current version of this protocol is
version 1.0; it was updated on February 18, 2020.
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